about
Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report.Microcirculatory effects of the transfusion of leukodepleted or non-leukodepleted red blood cells in patients with sepsis: a pilot study.Diet-induced unresolved ER stress hinders KRAS-driven lung tumorigenesis.Plasma free hemoglobin and microcirculatory response to fresh or old blood transfusions in sepsis.Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets.Characterization of the c-Myb-responsive region and regulation of the human type I collagen alpha 2 chain gene by c-Myb.Certolizumab pegol for the treatment of psoriasis.Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis.Aseptic inflammation of prosthetic knee in a patient affected by rheumatoid arthritis.A new HLA-DRB1*11 allele, DRB1*1144, identified by cloning and sequencing.Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.HLA-B*4904, a new allele identified in two unrelated individuals from the same Italian region.A novel HLA-Cw*16 allele, Cw*160102, identified by cloning and sequencing.The DETection of Arthritis in Inflammatory boweL diseases (DETAIL) questionnaire: development and preliminary testing of a new tool to screen patients with inflammatory bowel disease for the presence of spondyloarthritis.Biologics in inflammatory and immunomediated arthritis.Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease.Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti-Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies.Collagen loss and impaired wound healing is associated with c-Myb deficiency.Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts.Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the LiteratureExpression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA)Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis5-Methylcytosine content of DNA in blood, synovial mononuclear cells and synovial tissue from patients affected by autoimmune rheumatic diseasesMonocytes of patients wiht systemic sclerosis (scleroderma spontaneously release in vitro increased amounts of superoxide anionStimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host diseaseWidespread painful nodules in a patient with rheumatoid arthritisPreliminary validation of the Simplified Psoriatic Arthritis Radiographic Score (SPARS)Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinicBiomarkers in Inflammatory Bowel Disease-Associated Spondyloarthritis: State of the Art and Unmet NeedsClinical and patient reported outcomes of the multidisciplinary management in patients with inflammatory bowel disease-associated spondyloarthritisReply
P50
Q33420286-56412569-1E61-4808-8DFB-515D0C139C35Q33754405-F588EC10-F2D9-4617-A45E-2FE59877ED4DQ35008552-D29199F4-2AF9-4996-A0D1-72C4EAC9AC7BQ35560929-8AFF412D-7BBE-4F8B-AB40-6FEBC9EF75F8Q37012534-A078DB5C-F76F-44DA-A9A4-CA35F5F85306Q38361182-F8A3ED1F-8BC5-42FF-89C9-163C2C12E43AQ38976796-767A6428-3554-4610-A535-F40C01C50FD7Q40378949-8F51A659-C871-4292-88DA-481CD21884C8Q40425834-321D9EE1-3DF8-4F97-8AC5-8A2B93D88696Q44780127-408F9522-0BDC-4F85-8CFD-0DC572113313Q47132472-28D4381F-E5F5-4FA2-9FBC-084CE37A0E1CQ48086750-C98F2983-F1E8-489A-AAEA-82F40719015AQ48137751-2669EBEC-21B4-4CA6-81BF-BB468B7BDD5BQ48543621-1755EA71-422C-444E-88BB-1D233BB7A7F2Q49575282-63AC62B0-21ED-421D-B5DD-49A362450523Q50118739-A3BC0973-7669-400D-82ED-8D42D54EB345Q50243147-4D35EB9D-BFDC-440C-A836-BDB88899D42BQ54568455-A22236CB-DF44-428D-8E9E-7DF81E2D6B78Q54650316-E28F89B6-323F-4A92-8EC9-A26B67091E03Q56893186-C7FD7D19-8C59-40EB-93BD-26B285A7478EQ56943278-FA2DC0AC-3701-47F3-ACF9-9985E04271B7Q63283070-EBF16493-73A9-4F19-80DE-CDF15126E834Q68041572-FAEB422A-EA1C-4D3A-ACB6-2D4BB137C6C4Q77787177-90A9DB87-D74F-43F5-95EF-AF15ABA80475Q79961518-762C86ED-619A-4501-8E03-31CCC2E3DA81Q88010206-70038236-69D1-41B3-A63A-4E9B8A21CA5EQ90394986-9E08E6CE-AB54-4366-8ACE-8883BF561396Q90593383-45D70398-C97B-407B-B790-B6B0FE9D776AQ91645594-BBE0F5D7-2CE6-478B-9761-287764CE2AD2Q91705649-7C431622-B43D-4578-A3ED-52BF957EB07BQ95519886-DBDB961D-8257-4C21-9DA7-9B31A0A21EFE
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-9132-7401
@en
name
Michele Maria Luchetti
@ast
Michele Maria Luchetti
@en
Michele Maria Luchetti
@es
Michele Maria Luchetti
@nl
type
label
Michele Maria Luchetti
@ast
Michele Maria Luchetti
@en
Michele Maria Luchetti
@es
Michele Maria Luchetti
@nl
prefLabel
Michele Maria Luchetti
@ast
Michele Maria Luchetti
@en
Michele Maria Luchetti
@es
Michele Maria Luchetti
@nl
P106
P1153
7003266501
P21
P31
P496
0000-0001-9132-7401